Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naïve EGFR L858R-Induced Lung Adenocarcinoma

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Clinical Cancer Research

• Publication date

  2015-09-04

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-15-0620PMID 26341921PMCID PMC4715986
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Rociletinib in EGFR-mutated non-small-cell lung cancer.

  2015cited by this paper
• Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.

  2015cited by this paper
• Evidence that synthetic lethality underlies the mutual exclusivity of oncogenic KRAS and EGFR mutations in lung adenocarcinoma

  2015cited by this paper
• AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.

  2015cited by this paper
• Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations.

  2014cited by this paper
• Optimizing the Sequence of Anti-EGFR–Targeted Therapy in EGFR-Mutant Lung Cancer

  2014cited by this paper
• AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.

  2014cited by this paper
• Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1.

  2014cited by this paper
• Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients with EGFR inhibitor-resistant non-small cell lung cancer.

  2014cited by this paper
• Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

  2013cited by this paper
• Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.

  2013cited by this paper
• HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation.

  2012cited by this paper
• Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

  2012cited by this paper
• Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1

  2012cited by this paper
• A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer.

  2011cited by this paper
• Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

  2011cited by this paper
• Optimization of Dosing for EGFR-Mutant Non–Small Cell Lung Cancer with Evolutionary Cancer Modeling

  2011cited by this paper
• Hepatocyte Growth Factor Reduces Susceptibility to an Irreversible Epidermal Growth Factor Receptor Inhibitor in EGFR-T790M Mutant Lung Cancer

  2010cited by this paper
• Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in advanced nonsmall-cell lung cancer

  2010cited by this paper
• Erlotinib resistance in mouse models of epidermal growth factor receptor-induced lung adenocarcinoma

  2010cited by this paper
• Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer.

  2009cited by this paper
• Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity.

  2007cited by this paper
• MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

  2007cited by this paper
• Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy.

  2007cited by this paper
• Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors

  2006cited by this paper
• Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors.

  2006cited by this paper
• BioImage Suite: An integrated medical image analysis suite: An update.

  2006cited by this paper
• Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

  2005cited by this paper
• KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib

  2005cited by this paper
• EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

  2004influential reference
• EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.

  2004cited by this paper
• Genetics of murine lung tumors.

  1995cited by this paper

• From EGFR mutations to STAT30-driven resistance in NSCLC: Biomarkers and multi-modal treatment approach.

  2025cites this paper
• Identification of potent biparatopic antibodies targeting FGFR2 fusion–driven cholangiocarcinoma

  2025cites this paper
• RNA methylation of CD47 mediates tumor immunosuppression in EGFR-TKI resistant NSCLC

  2025influential citation
• Targeting TAM-secreted S100A9 effectively enhances the tumor-suppressive effect of metformin in treating lung adenocarcinoma.

  2023cites this paper
• A randomized, open-label, two-cycle, two-crossover phase I clinical trial comparing the bioequivalence and safety of afatinib and Giotrif^® in healthy Chinese subjects

  2022cites this paper
• AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer

  2022cites this paper
• “Sandwich” Strategy to Intensify EGFR Blockade by Concurrent Tyrosine Kinase Inhibitor and Monoclonal Antibody Treatment in Highly Selected Patients

  2022influential citation
• Circulating tumor DNA (ctDNA) kinetics predict progression-free and overall survival in EGFR TKI-treated patients with EGFR-mutant NSCLC (SWOG S1403).

  2022cites this paper
• First-Line Afatinib plus Cetuximab for EGFR-Mutant Non–Small Cell Lung Cancer: Results from the Randomized Phase II IFCT-1503 ACE-Lung Study

  2021cites this paper
• Emerging therapies for non-small cell lung cancer harboring EGFR exon 20 insertion mutations: narrative review

  2021cites this paper
• Iterative Upgrading of Small Molecular Tyrosine Kinase Inhibitors for EGFR Mutation in NSCLC: Necessity and Perspective

  2021cites this paper
• Preclinical Models for the Study of Lung Cancer Pathogenesis and Therapy Development.

  2021cites this paper
• HSP90 inhibition overcomes EGFR amplification‐induced resistance to third‐generation EGFR‐TKIs

  2021cites this paper
• Genetic determinants of EGFR-Driven Lung Cancer Growth and Therapeutic Response In Vivo

  2020cites this paper
• Immunotherapy of Lung Tumors

  2020cites this paper
• SFI Enhances Therapeutic Efficiency of Gefitinib: An Insight into Reversal of Resistance to Targeted Therapy in Non-small Cell Lung Cancer Cells

  2020cites this paper
• From the Clinic to the Bench and Back Again in One Dog Year: How a Cross-Species Pipeline to Identify New Treatments for Sarcoma Illuminates the Path Forward in Precision Medicine

  2020cites this paper
• Inhibition of miR-22 enhanced the efficacy of icotinib plus pemetrexed in a rat model of non-small cell lung cancer

  2020cites this paper
• Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance EGFR Mutations

  2020cites this paper
• Noninvasive quantification of target availability during therapy using paired-agent fluorescence tomography

  2020cites this paper
• Randomized Trial of Afatinib Plus Cetuximab Versus Afatinib Alone for First-Line Treatment of EGFR-Mutant Non-Small-Cell Lung Cancer: Final Results From SWOG S1403.

  2020cites this paper
• EGFR-directed monoclonal antibodies in combination with chemotherapy for treatment of non-small-cell lung cancer: an updated review of clinical trials and new perspectives in biomarkers analysis.

  2019cites this paper
• Beyond EGFR inhibition: multilateral combat strategies to stop the progression of head and neck cancer

  2019cites this paper
• Monomer Preference of EGFR Tyrosine Kinase Inhibitors Influences the Synergistic Efficacy of Combination Therapy with Cetuximab

  2019cites this paper
• From the clinic to the bench and back again in one dog year: identifying new treatments for sarcoma using a cross-species personalized medicine pipeline

  2019cites this paper
• Metformin and tenovin‐6 synergistically induces apoptosis through LKB1‐independent SIRT1 down‐regulation in non‐small cell lung cancer cells

  2019cites this paper
• Anti–Epidermal Growth Factor Vaccine Antibodies Enhance the Efficacy of Tyrosine Kinase Inhibitors and Delay the Emergence of Resistance in EGFR Mutant Lung Cancer Cells

  2018cites this paper
• TTF-1 and EGFR expression are related to EGFR mutation in lung adenocarcinoma.

  2018cites this paper
• Sensitivity to chemotherapeutics of NSCLC cells with acquired resistance to EGFR-TKIs is mediated by T790M mutation or epithelial-mesenchymal transition.

  2018cites this paper
• Mechanism of Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and a Potential Treatment Strategy

  2018cites this paper
• 用于治疗非小细胞肺癌的阿法替尼脂质体的制备与包封率的测定

  2018cites this paper
• Resistance to epidermal growth factor receptor tyrosine kinase inhibitors, T790M, and clinical trials.

  2018cites this paper
• MET Tyrosine Kinase Inhibition Enhances the Antitumor Efficacy of an HGF Antibody

  2017cites this paper
• Novel EGFR Inhibitors in Non-small Cell Lung Cancer: Current Status of Afatinib

  2017cites this paper
• Chapter 25 – Afatinib

  2017cites this paper
• Overcoming On-Target Resistance to Tyrosine Kinase Inhibitors in Lung Cancer

  2017cites this paper
• New strategies for targeting drug combinations to overcome mutation-driven drug resistance.

  2017cites this paper
• Tumour heterogeneity and resistance to cancer therapies

  2017cites this paper
• Afatinib + Cetuximab First-line in EGFR-Mutant Lung Cancer—Letter

  2016cites this paper
• Oncogenic EGFR Represses the TET1 DNA Demethylase to Induce Silencing of Tumor Suppressors in Cancer Cells.

  2016cites this paper
• Study of the combined treatment of lung cancer using gene-loaded immunomagnetic albumin nanospheres in vitro and in vivo

  2016cites this paper
• Emerging role of mTOR in the response to cancer therapeutics.

  2016cites this paper
• Enhanced Antitumor Activity of Cetuximab in Combination with the Jak Inhibitor CYT387 against Non-Small-Cell Lung Cancer with Various Genotypes.

  2016cites this paper